Radiation plus Chemo-Immunotherapy shows promise in High-Risk breast cancer trial
NCT ID NCT07254858
First seen Jan 04, 2026 · Last updated May 07, 2026 · Updated 23 times
Summary
This study tests whether adding targeted radiation to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will receive either chemo-immunotherapy alone or with radiation. The goal is to see if the combination leads to a higher chance of eliminating the tumor before surgery and improving long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.